Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 7/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | SRC | P12931 | 6/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.47 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.46 |
| ▸ | WNT3A | P56704 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2319091 | 0.79 | NOTUM (0.56) | CHEK1NOTUMMTOREGFRMAP3K7 | |
| SCHEMBL13101606 | 0.79 | ABL1 (0.57) | CHEK1NOTUMMTORMAP3K7MAP3K6 | |
| SCHEMBL12410299 | 0.79 | PIK3CA (0.57) | CHEK1NOTUMMTORMAPK1 | |
| SCHEMBL28166698 | 0.78 | GSK3B (0.60) | CHEK1NOTUMMTORMAP3K7MAP3K6 | |
| SCHEMBL30636341 | 0.78 | GSK3B (0.60) | CHEK1NOTUMMTORMAP3K7MAP3K6 | |
| SCHEMBL2841751 | 0.77 | NOTUM (0.57) | CHEK1NOTUMMTORMAP3K7MAP3K6 | |
| SCHEMBL177776 | 0.77 | RAB9A (0.63) | CHEK1NOTUMMTORPDGFRBPDGFRA | |
| SCHEMBL2549206 | 0.76 | CHEK1 (0.55) | CHEK1NOTUMMTORWNT3AKDM4E | |
| SCHEMBL14185051 | 0.75 | CYP1A2 (0.48) | CHEK1NOTUMMTOREGFRWNT3A | |
| SCHEMBL8432118 | 0.75 | EGLN1 (0.52) | MTORPDGFRBPDGFRAEGFRCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003662-B2 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-06-02 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ARRAY BIOPHARMA, INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197537-A1 | Heterobicyclic thiophene compounds and methods of use | ERBB2, LCK, SRC | CHEK1 404/4885FGFR1 28/4885NOTUM 2701/4885 |
| US-20110130406-A1 | PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS | TYRO3, LCK, LTK | CHEK1 436/4885FGFR1 34/4885NOTUM 4744/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | CHEK1 575/4885FGFR1 25/4885NOTUM 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.